The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or “the Company”) (NASDAQ: YMAB) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Y-mAbs is the subject of briefing documents posted to the FDA website on October 26, 2022. According to the documents, FDA scientists have identified concerns with the data submitted as part of the Company’s Biologics License Application (BLA) for omburtamab. The FDA identified multiple issues with the Company’s data, including the differences between its study and control populations. Based on this news, shares of Y-mAbs fell by more than 23% in intraday trading on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221027005770/en/